Merck announced the first results from the Phase 3 CORALreef HeFH trial, showing that its investigational drug enlicitide decanoate, a once-daily oral PCSK9 inhibitor, reduced LDL-C by 59.4% compared to placebo in adults with heterozygous familial hypercholesterolemia (HeFH) after 24 weeks. Read full news here:https://www.coherentmarketinsights.com/news/mercks-enlicitide-decanoate-lo... https://www.coherentmarketinsights.com/news/mercks-enlicitide-decanoate-lowers-ldl-c-in-hefh-adults-1843